Article
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
Oncotarget - 4 Jul 2017
Dougherty Brian A, Lai Zhongwu, Hodgson Darren R, Orr Maria C M, Hawryluk Matthew, Sun James, Yelensky Roman, Spencer Stuart K, Robertson Jane D, Ho Tony W, Fielding Anitra, Ledermann Jonathan A, Barrett J Carl
Abstract excerpt
To gain a better understanding of the role of somatic mutations in olaparib response, next-generation sequencing (NGS) of BRCA1 and BRCA2 was performed as part of a planned retrospective analysis of tumors from a randomized, double-blind, Phase II trial (Study 19; D0810C00019; NCT00753545) in 265 patients with platinum-sensitive high-grade serous ovarian cancer. BRCA1/2 loss-of-function mutations were found in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.